-
News
- Technology /AI
- Medical journals
- Topics
News
Levodropropizine – a non-codeine antitussive with minimal side effects, contraindications, and drug interactions
10. 1. 2022 Source: Cough TherapyFor symptomatic treatment of dry, irritating, and exhausting cough, both codeine and non-codeine antitussives can be used. One of the non-codeine antitussives is levodropropizine. Its antitussive effect is comparable to centrally acting codeine antitussives, but with a significantly lower incidence of side effects. Compared to codeine, it has a much narrower range of contraindications, and no interactions with benzodiazepines or drugs used in the treatment of bronchopulmonary diseases have been observed.
From Hell to the Light at the End of the Tunnel – A Task for Eletriptan
In recent months, under the spotlight of new biological treatments, the focus has been predominantly on the prophylactic treatment of migraines. However, we should not forget about acute therapy. In…4. 1. 2022 Source: Treatment of Severe Migraine
Brentuximab Vedotin as Another Therapeutic Option in Cutaneous T-Cell Lymphoma
Current systemic treatment for patients with cutaneous T-cell lymphoma (CTCL) unfortunately has limited efficacy, achieving low response rates and short-lasting remissions. Moreover, there is no…4. 1. 2022 Source: Hematologic Malignancies
Current Recommendations of the Expert Panel on the Management of von Willebrand Disease
Von Willebrand disease (vWD) is a common congenital bleeding disorder. The care of patients with vWD involves significant variability due to bleeding manifestations and treatment options. The new…4. 1. 2022 Source: Von Willebrand Disease
How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients
Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They affect both specific and nonspecific immunity and are classified accordingly. The care for patients with…3. 1. 2022 Source: Hereditary Angioedema
Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP was released. Let's take a look at what changes it has brought compared to the previous version in…27. 12. 2021 Source: Genetic Profile and Treatment of NSCLC
Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk of intracranial bleeding. Prophylactic and therapeutic interventions for blood clotting are necessary for…27. 12. 2021 Source: Genetic Profile and Treatment of NSCLC
Complete remission of ALK-positive lung cancer in a patient after multiple lines of targeted therapy – a case study
Targeted treatment for driving oncogenic mutations has significantly improved outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC) as well. A case study was recently published…27. 12. 2021 Source: Genetic Profile and Treatment of NSCLC
How Do Vaccinated MS Patients Fare with COVID-19 Antibodies?
Which disease-modifying drugs for the treatment of multiple sclerosis (MS) reduce the humoral response to COVID-19 vaccination? And does the quantity of post-vaccination antibodies vary depending on…21. 12. 2021 Source: Multiple Sclerosis
When Teriflunomide and Interferon Join Forces
Progressive multifocal leukoencephalopathy is a nightmare for all doctors prescribing disease-modifying therapies for multiple sclerosis. How Swiss colleagues dealt with this situation is illuminated…21. 12. 2021 Source: Multiple Sclerosis
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Technology /AI